Anhui Taienkang Pharmaceutical Co., Ltd.

Main study purpose: This study uses indobufen tablets (specification: 0.2g) produced by Anhui Taienkang Pharmaceutical Co., Ltd. as the test preparation and indobufen tablets (specification: 0.2g, trade name: Ibustrin ®) certified by Pfizer Italia S.r.l as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting and postprandial conditions. Secondary study purpose: To observe the safety of a single oral dose of 0.2g of indobufen tablets test preparation or reference preparation in healthy subjects.

Main purpose To compare the differences in absorption extent and speed of dienogest tablets (2 mg) provided by Anhui Taienkang Pharmaceutical Co., Ltd. and dienogest tablets (2 mg, trade name: Visanning®) certified by Jenapharm GmbH & Co. KG in healthy adults under the condition of postprandial administration, and to evaluate their bioequivalence. Secondary purpose To evaluate the safety of dienogest tablets (2 mg) provided by Anhui Taienkang Pharmaceutical Co., Ltd. and dienogest tablets (2 mg, trade name: Visanning®) certified by Jenapharm GmbH & Co. KG under the condition of postprandial administration.

Primary objective To compare the differences in the extent and rate of absorption of safinamide mesylate tablets (100 mg) provided by Anhui Taienkang Pharmaceutical Co., Ltd. and safinamide mesylate tablets (100 mg; trade name: Xadago ®) licensed by Zambon S.p.A. in healthy adults under fasting conditions, and to evaluate their bioequivalence. Secondary objective To evaluate the safety of safinamide mesylate tablets (100 mg) provided by Anhui Taienkang Pharmaceutical Co., Ltd. and safinamide mesylate tablets (100 mg; trade name: Xadago ®) licensed by Zambon S.p.A. under fasting conditions.